Purple Biotech (PPBT) Consolidated Net Income (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Consolidated Net Income data on file, last reported at $2.2 million in Q1 2026.

• Consolidated Net Income for Q1 2026 came in at $2.2 million, up 67.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.3 million (up 362.89% YoY), and the FY2025 annual result was $26.1 million, up 169.86% from the prior year.
• Consolidated Net Income fell to $2.2 million in Q1 2026 per PPBT's latest filing, from $22.8 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $22.8 million in Q4 2025 and troughed at $217000.0 in Q4 2024.
• A 5-year average of $4.5 million and a median of $4.3 million in 2022 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2022 and 2024: Consolidated Net Income soared 215300.0% in 2022, then tumbled 93.19% in 2024.
• A 5-year view of Consolidated Net Income shows it stood at $5.7 million in 2022, then tumbled by 44.49% to $3.2 million in 2023, then plunged by 93.19% to $217000.0 in 2024, then soared by 10410.6% to $22.8 million in 2025, then sank by 90.35% to $2.2 million in 2026.
• Business Quant data shows PPBT's Consolidated Net Income at $2.2 million in Q1 2026, $22.8 million in Q4 2025, and $1.1 million in Q3 2025.